Review found that fewer than 60% of patients with chronic inflammatory skin diseases underwent recommended testing before starting systemic immunomodulator treatment.
The European Commission published its first list of critical medicines, as part of a wider overhaul of laws governing the 136 billion euro ($148 billion) pharmaceuticals.